Histone deacetylase inhibitors and methods of use thereof

Details Histone deacetylase inhibitors and methods of use thereof Histone deacetylase inhibitors and methods of use thereof

2008-12-19

2011-11-29

Desai, Rita (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S152000, C546S314000, C546S339000, C514S307000, C514S311000, C514S354000

Reexamination Certificate

active

08067600

ABSTRACT:
One aspect of the invention relates to HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided. The invention also provides methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.

REFERENCES:
patent: 4028401 (1977-06-01), Fessler et al.
patent: 4122186 (1978-10-01), Lafon et al.
patent: 5310536 (1994-05-01), Srinivasan
patent: 5656253 (1997-08-01), Rajagopalan et al.
patent: 5700811 (1997-12-01), Breslow et al.
patent: 5776494 (1998-07-01), Guskey et al.
patent: 6495719 (2002-12-01), Lan-Hargest et al.
patent: 6511990 (2003-01-01), Breslow et al.
patent: 7507828 (2009-03-01), Kozikowski et al.
patent: 2002/0103192 (2002-08-01), Curtin et al.
patent: 2002/0115826 (2002-08-01), Delorme et al.
patent: 2002/0143037 (2002-10-01), Lan-Hargest et al.
patent: 2002/0143052 (2002-10-01), Lan-Hargest et al.
patent: 2002/0143196 (2002-10-01), Lan-Hargest et al.
patent: 2005/0119305 (2005-06-01), Naka et al.
patent: WO-93/07148 (1993-04-01), None
patent: WO-95/31977 (1995-11-01), None
patent: WO-98/18754 (1998-05-01), None
patent: WO-01/38322 (2001-05-01), None
patent: WO-01/70675 (2001-09-01), None
patent: WO-01/70734 (2001-09-01), None
patent: WO-02/26696 (2002-04-01), None
patent: WO-02/074298 (2002-09-01), None
patent: WO-02/076941 (2002-10-01), None
Bjorklund et al., “Global transcription regulators of eukaryotes,” Cell 96(6):759-67 (1999).
Caplus English Abstract, DN 48:11270 GB 679323 Aktiebolaget Pharmacia (1952).
Dai et al., “Indole amide hydroxamic acids as potent inhibitors of histone deacetylases,” Bioorg Med Chem Lett. 13(11):1897-901 (2003).
Hilger et al., “Tc(V) and Re(V) complexes of N-(mercaptoacetyl-glycyl)-histamine,” Database accession No. 1998:190659, Abstract, XP-002430349.
Jackson et al., “DNA double-strand break repair and V(D)J recombination: involvement of DNA-PK.” Elsevier Sc. Ltd., 20(10):412-415 (1995).
Katsarava et al., “Role of complex formation during polycondensation of activated N-hydroxysuccinimide esters with diamines,” Database accession No. 1984:531205, Abstract, XP-002430347.
Kornberg et al., “Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome,” Cell 98(3):285-294 (1999).
Kornyei et al., “99mTc-labeling of mercaptoacetyltriglycine and its related compounds,” Database accession No. 1994:186299, Abstract, XP-002430351.
Martirosyan et al., “Differentiation-inducing quinolines as experimental breast cancer agents in the MCF-7 human breast cancer cell model,” Biochemical Pharmacology, 68:1729-1738 (2004).
Methot et al., “Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2),” Biorg. Med. Chem. Lett., doi:10.1016/j.bmcl.2007.12.031 (2008).
Meyn, MS, “Ataxia-telangiectasia and cellular responses to DNA damage,” J. Am Assoc. for Cancer Res., 55(24):5991-6001 (1995).
Noll et al, “Note on the fast hydrolsis of the methyl ester of mercaptoacetyl diglycine during complexation with Tc/Re(v) gluconate,” Database accession No. 1997:321173, Abstract, XP-002430350.
Oleinick et al., “Nuclear structure and the microdistribution of radiation damage in DNA,” Int. J. Radiat. Biol., 66(5):523-529 (1994).
Ommeslaeghe, et al., “Amide analogues of TSA: synthesis, binding mode analysis and HDAC inhibition.” Bioorg Med Chem Lett., 13(1.1):1861-4 (2003).
Ranadive et al., “Reactions of amines with N-hydroxy-, (2,3-epoxypropoxy) succinimide and -naptthalimide,” Database accession No. 1995:333422, Abstract, XP-002430348.
Ranadive & Samant, “Reactions of amines with N-hydroxy-, N-(2,3-epoxypropoxy)-succinimide and naphthalimide,” Indian Journal of Chemistry, 34B:102-106 (1995).
Richon et al., “A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases,” Proc. Natl. Acad. Sci. USA, 95:3003-3007 (1998).
Siliphaivanh et al., “Design of novel histone deacetylase inhibitors,” Bioorg. Med. Chem. Lett., 17:4619-4624 (2007).
Sternson et al., “Synthesis of 7200 Small Molecules Based on a Substructural Analysis of the Histone Deacetylase Inhibitors Trichostatin and Trapoxin,” Organic Letters 3(26):4239-4242 (2001).
Stockdale FE, “Ch IV: Principle of cancer patient management,” In 12: Oncology, In Scientific American Medicine, vol. 3, NY: Scientific American, Inc.: 1-10 (1978).
Struhl et al., “The TAFs in the HAT,” Cell. 94(1):1-4 (1998).
Weichselbaum et al., “Heterogeneity of radiation response of a parent human epidermoid carcinoma cell line and four clones,” IntJRadial Oncol Biol Phys. 14(5):907-12 (1988).
Zhang et al., “HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo,” EMBO J.;22(5):1168-79 (2003).

Affiliated with

Also associated with

Rating

Histone deacetylase inhibitors and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Histone deacetylase inhibitors and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Histone deacetylase inhibitors and methods of use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4308759